JP2015528802A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015528802A5 JP2015528802A5 JP2015522098A JP2015522098A JP2015528802A5 JP 2015528802 A5 JP2015528802 A5 JP 2015528802A5 JP 2015522098 A JP2015522098 A JP 2015522098A JP 2015522098 A JP2015522098 A JP 2015522098A JP 2015528802 A5 JP2015528802 A5 JP 2015528802A5
- Authority
- JP
- Japan
- Prior art keywords
- her2 antibody
- fucose
- composition according
- her2
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims description 27
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 claims description 27
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 claims description 27
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 20
- 238000011282 treatment Methods 0.000 claims description 16
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 13
- 206010028980 Neoplasm Diseases 0.000 claims description 13
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 13
- 201000011510 cancer Diseases 0.000 claims description 13
- 206010027476 Metastases Diseases 0.000 claims description 12
- 239000002246 antineoplastic agent Substances 0.000 claims description 10
- 150000001720 carbohydrates Chemical group 0.000 claims description 8
- 229940127089 cytotoxic agent Drugs 0.000 claims description 8
- 230000001225 therapeutic effect Effects 0.000 claims description 8
- 206010027457 Metastases to liver Diseases 0.000 claims description 6
- 206010027458 Metastases to lung Diseases 0.000 claims description 6
- 210000004072 lung Anatomy 0.000 claims description 6
- 206010040882 skin lesion Diseases 0.000 claims description 6
- 231100000444 skin lesion Toxicity 0.000 claims description 6
- 230000009278 visceral effect Effects 0.000 claims description 6
- 238000002648 combination therapy Methods 0.000 claims description 5
- 206010027465 Metastases to skin Diseases 0.000 claims description 4
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 claims description 4
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 claims description 4
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 claims description 4
- 208000025865 Ulcer Diseases 0.000 claims description 4
- 230000037396 body weight Effects 0.000 claims description 4
- 230000013595 glycosylation Effects 0.000 claims description 4
- 238000006206 glycosylation reaction Methods 0.000 claims description 4
- 210000001165 lymph node Anatomy 0.000 claims description 4
- 238000001959 radiotherapy Methods 0.000 claims description 4
- 238000009097 single-agent therapy Methods 0.000 claims description 4
- 229960000575 trastuzumab Drugs 0.000 claims description 4
- 208000037819 metastatic cancer Diseases 0.000 claims description 3
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 206010055113 Breast cancer metastatic Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 claims description 2
- 101710099301 Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 208000008771 Lymphadenopathy Diseases 0.000 claims description 2
- 208000007433 Lymphatic Metastasis Diseases 0.000 claims description 2
- 206010027459 Metastases to lymph nodes Diseases 0.000 claims description 2
- SQVRNKJHWKZAKO-LUWBGTNYSA-N N-acetylneuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)CC(O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-LUWBGTNYSA-N 0.000 claims description 2
- FDJKUWYYUZCUJX-KVNVFURPSA-N N-glycolylneuraminic acid Chemical compound OC[C@H](O)[C@H](O)[C@@H]1O[C@](O)(C(O)=O)C[C@H](O)[C@H]1NC(=O)CO FDJKUWYYUZCUJX-KVNVFURPSA-N 0.000 claims description 2
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 claims description 2
- 206010061934 Salivary gland cancer Diseases 0.000 claims description 2
- 206010040943 Skin Ulcer Diseases 0.000 claims description 2
- 208000013228 adenopathy Diseases 0.000 claims description 2
- QIGJYVCQYDKYDW-SDOYDPJRSA-N alpha-D-galactosyl-(1->3)-D-galactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@H]1[C@@H](O)[C@@H](CO)OC(O)[C@@H]1O QIGJYVCQYDKYDW-SDOYDPJRSA-N 0.000 claims description 2
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims description 2
- 208000014581 breast ductal adenocarcinoma Diseases 0.000 claims description 2
- 201000010983 breast ductal carcinoma Diseases 0.000 claims description 2
- 229930182830 galactose Natural products 0.000 claims description 2
- 229940022353 herceptin Drugs 0.000 claims description 2
- 238000003364 immunohistochemistry Methods 0.000 claims description 2
- 206010073095 invasive ductal breast carcinoma Diseases 0.000 claims description 2
- 230000003902 lesion Effects 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 229940060155 neuac Drugs 0.000 claims description 2
- CERZMXAJYMMUDR-UHFFFAOYSA-N neuraminic acid Natural products NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO CERZMXAJYMMUDR-UHFFFAOYSA-N 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 230000002018 overexpression Effects 0.000 claims description 2
- 201000001219 parotid gland cancer Diseases 0.000 claims description 2
- 229960002087 pertuzumab Drugs 0.000 claims description 2
- 230000002250 progressing effect Effects 0.000 claims description 2
- 231100000019 skin ulcer Toxicity 0.000 claims description 2
- 238000001356 surgical procedure Methods 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261673216P | 2012-07-18 | 2012-07-18 | |
| US201261673201P | 2012-07-18 | 2012-07-18 | |
| US201261673229P | 2012-07-18 | 2012-07-18 | |
| US61/673,229 | 2012-07-18 | ||
| US61/673,201 | 2012-07-18 | ||
| US61/673,216 | 2012-07-18 | ||
| EP12197768.0 | 2012-12-18 | ||
| EP12197768 | 2012-12-18 | ||
| PCT/EP2013/065189 WO2014013019A1 (en) | 2012-07-18 | 2013-07-18 | Novel therapeutic treatments with anti-her2 antibodies having a low fucosylation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015528802A JP2015528802A (ja) | 2015-10-01 |
| JP2015528802A5 true JP2015528802A5 (enExample) | 2016-09-08 |
Family
ID=49948317
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015522098A Pending JP2015528802A (ja) | 2012-07-18 | 2013-07-18 | フコシル化が低い抗ｈｅｒ２抗体を用いた新規治療処置 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20150166664A1 (enExample) |
| EP (1) | EP2874658A1 (enExample) |
| JP (1) | JP2015528802A (enExample) |
| KR (1) | KR20150036710A (enExample) |
| CN (1) | CN104394887A (enExample) |
| AU (1) | AU2013291964B2 (enExample) |
| BR (1) | BR112014032169A2 (enExample) |
| CA (1) | CA2875486A1 (enExample) |
| EA (1) | EA201590237A1 (enExample) |
| IL (1) | IL236714A0 (enExample) |
| MA (1) | MA37961A1 (enExample) |
| MX (1) | MX2015000730A (enExample) |
| NZ (1) | NZ701974A (enExample) |
| SG (1) | SG11201407841YA (enExample) |
| WO (1) | WO2014013019A1 (enExample) |
| ZA (1) | ZA201408938B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LU92659B1 (en) * | 2015-02-23 | 2016-08-24 | Glycotope Gmbh | Glycooptimized antibody drug conjugates |
| CA3057758A1 (en) * | 2017-03-29 | 2018-10-04 | Glycotope Gmbh | Pd-l1 and ta-muc1 antibodies |
| ES2995219T3 (en) * | 2018-06-15 | 2025-02-07 | Shanghai Miracogen Inc | Methods and materials for treating cancer |
| CN112955137B (zh) | 2018-09-10 | 2025-05-13 | 米拉蒂治疗股份有限公司 | 组合疗法 |
| EP4190818A4 (en) * | 2020-07-28 | 2024-08-07 | Bio-Thera Solutions, Ltd. | ANTI-HER2 ANTIBODY AND ITS USE |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101155191B1 (ko) | 1999-01-15 | 2012-06-13 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
| ES2568899T3 (es) | 1999-04-09 | 2016-05-05 | Kyowa Hakko Kirin Co., Ltd. | Procedimiento para controlar la actividad de una molécula inmunofuncional |
| DE60114830T2 (de) | 2000-06-28 | 2006-08-03 | Glycofi, Inc. | Verfahren zur herstellung modifizierter glycoproteine |
| ES2326964T3 (es) | 2001-10-25 | 2009-10-22 | Genentech, Inc. | Composiciones de glicoproteina. |
| EP1500400A4 (en) | 2002-04-09 | 2006-10-11 | Kyowa Hakko Kogyo Kk | MEDICAMENT CONTAINING ANTIBODY COMPOSITION |
| JP5425365B2 (ja) * | 2003-01-22 | 2014-02-26 | グリカート バイオテクノロジー アクチェンゲゼルシャフト | 増加したＦｃレセプター結合親和性およびエフェクター機能を有する抗体を作製するための融合構築物およびその使用 |
| FR2858235B1 (fr) | 2003-07-31 | 2006-02-17 | Lab Francais Du Fractionnement | Utilisation d'anticorps optimises en adcc pour traiter les patients faibles repondeurs |
| JPWO2005053742A1 (ja) * | 2003-12-04 | 2007-06-28 | 協和醗酵工業株式会社 | 抗体組成物を含有する医薬 |
| US7273608B2 (en) * | 2004-03-11 | 2007-09-25 | City Of Hope | Humanized anti-CEA T84.66 antibody and uses thereof |
| DOP2006000029A (es) * | 2005-02-07 | 2006-08-15 | Genentech Inc | Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas) |
| PT2073842E (pt) * | 2006-09-10 | 2015-04-07 | Glycotope Gmbh | Utilização de células humanas provenientes de uma leucemia mielóide para expressão de anticorpos |
| CA2776385C (en) * | 2009-10-07 | 2019-04-09 | Macrogenics, Inc. | Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use |
| US20120258496A1 (en) * | 2010-09-27 | 2012-10-11 | Boehringer Ingelheim International Gmbh | Production of low fucose antibodies in h4-ii-e rat cells |
-
2013
- 2013-07-18 US US14/412,797 patent/US20150166664A1/en not_active Abandoned
- 2013-07-18 MA MA37961A patent/MA37961A1/fr unknown
- 2013-07-18 EP EP13739973.9A patent/EP2874658A1/en not_active Withdrawn
- 2013-07-18 JP JP2015522098A patent/JP2015528802A/ja active Pending
- 2013-07-18 MX MX2015000730A patent/MX2015000730A/es unknown
- 2013-07-18 EA EA201590237A patent/EA201590237A1/ru unknown
- 2013-07-18 WO PCT/EP2013/065189 patent/WO2014013019A1/en not_active Ceased
- 2013-07-18 NZ NZ701974A patent/NZ701974A/en not_active IP Right Cessation
- 2013-07-18 CN CN201380034959.0A patent/CN104394887A/zh active Pending
- 2013-07-18 CA CA2875486A patent/CA2875486A1/en not_active Abandoned
- 2013-07-18 SG SG11201407841YA patent/SG11201407841YA/en unknown
- 2013-07-18 BR BR112014032169A patent/BR112014032169A2/pt not_active IP Right Cessation
- 2013-07-18 KR KR20157004250A patent/KR20150036710A/ko not_active Withdrawn
- 2013-07-18 AU AU2013291964A patent/AU2013291964B2/en not_active Expired - Fee Related
-
2014
- 2014-12-05 ZA ZA2014/08938A patent/ZA201408938B/en unknown
-
2015
- 2015-01-14 IL IL236714A patent/IL236714A0/en unknown